Stem cells regenerate damaged pancreas

Preclinical trial results in mice show that a proprietary adult stem cell platform could be an effective treatment for diabetes.

Mesoblast: http://www.mesoblast.com.au/mediareleases/134.pdf

Mesoblast Limited (ASX: MSB) In the study at the Queen Elizabeth Hospital in Adelaide, South Australia, in collaboration with Mesoblast’s United States-based associate company Angioblast Systems Inc., a single dose of the patented human Mesenchymal Precursor Cells (MPCs) injected into mice with diabetes resulted in a significant increase in blood insulin levels and sustained reduction in blood glucose levels for the entire three week period of follow-up.